newsfilter
← Latest News
GlobeNewswire·

Decibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate Update

- Multiple milestones anticipated for 2022 including submission of IND and/or CTA for DB-OTO, top-line results from interim analysis of Phase 1b trial of DB-020 for cisplatin-induced hearing loss and product candidate selection for AAV.103 program –